Skip to content

ArriVent BioPharma

US · AVBP #3057 by market cap Listed 2024
10.52 -0.74 -6.57%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 10.95 -2.75%
After-hours 10.52 0.00%
34.7410.5210.522026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AVBP?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -55.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 11.8% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D-

How much profit the business keeps from each dollar of sales and capital.

Return on equity -58.9% Better than 8%
Return on invested capital -62.8% Better than 5%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -63.9% Better than 2%
6-month return -60.6% Better than 4%
12-month return (ex latest month) -5.7% Better than 26%
Distance below 52-week high 70.6% Better than 6%
Financial Health A+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 12.8x Better than 95%
Debt to assets 0.0% Better than 100%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 166.2% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -19.14%
1M -44.19%
3M -63.95%
6M -61.35%
YTD -47.71%
1Y -47.56%

Key statistics

Price & volume

Prev close
11.26
Open
11.00
Day range
10.38 - 11.35
Avg price
10.75
Volume
1.05M
Turnover
11.33M
Amplitude
8.62%
52-week range
10.33 - 35.83

Valuation

P/E
-2.44
P/E (TTM)
-2.92
P/B
1.38
EPS
-4.32
Net profit
-223.44M
Net assets
393.46M

Share structure

Market cap
544.13M
Float cap
331.50M
Shares out
51.72M
Float shares
31.51M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2024-01-26
52-week range 1% of range
10.33 35.83

70.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+6.49M net over the window

Short interest

Shares short
5.80M
As of
2026-10-30

Frequently asked questions

What is the current stock price of ArriVent BioPharma (AVBP)?

ArriVent BioPharma last traded at 10.52. This page shows a periodic quote snapshot. Check the displayed quote time.

What is ArriVent BioPharma's market cap?

About 544.13M.

What is the P/E ratio of ArriVent BioPharma?

The trailing twelve-month P/E is -2.92. The Valuation tab shows it against the stock's own five-year range.

Does ArriVent BioPharma pay a dividend?

ArriVent BioPharma does not currently pay a regular dividend.

Is ArriVent BioPharma a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 28.00, which implies 166.2% upside from the current price. This is not investment advice.

What is ArriVent BioPharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates ArriVent BioPharma a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ArriVent BioPharma discussion 0 comments

Add a comment